Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 431-435

  Yilmaz, Mehmet Birhan ^a   Yalta, Kenan ^a   Yontar, Can ^a   Karadas, Filiz ^a   Erdem, Alim ^a   Turgut, Okan Onur ^a   Yilmaz, Ahmet ^a   Tandogan, Izzet ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Dobutamine; Glomerular filtration rate; Heart failure; Levosimendan; Renal function

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FUROSEMIDE; LEVOSIMENDAN; NITROGEN; UREA;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INOTROPISM; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE VOLUME;

ACUTE DISEASE; AGED; CARDIOTONIC AGENTS; DOBUTAMINE; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYDRAZONES; KIDNEY; MALE; MIDDLE AGED; PYRIDAZINES; URINATION;

EID: 36849013485     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6066-7     Document Type: Article

References (22)

1. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38:1782.
2. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care. 2004;10:436-41.
3. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol. 2005;288:H914-22.
4. Levey AS, Bosch JP, Lewis JB, Greene T, Rodgers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-70.
5. Benedict CR, Rose JA. Arterial norepinephrine changes in patients with septic shock. Circ Shock. 1992;38:165-72.
6. Boim MA, Draibe SA, Ramos OL, Ajzen H, Ulmann A, Schor N. Glomerular hemodynamics during abortion induced by RU 486 and sepsis in rats. Braz J Med Biol Res. 1994;27:1431-44.
7. Lugon JR, Boim MA, Ajzen H, Schor N. Renal function and glomerular hemodynamics in male endotoxemic rats. Kidney Int. 1989;36:570-75.
8. Schrier RW, Wang W. Acute renal failure and sepsis. N Eng J Med. 2004;351:159-69.
9. Goldfarb M, Abassi Z, Rosen S, Shina A, Brezis M, Heyman SN. Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int. 2001;60:607-13.
10. Tiwari MM, Brock RW, Megyesi JK, Kaushal GP, Mayeux PR. Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure. Role of nitric oxide and caspases. Am J Physiol Renal Physiol. 2005;289:F1324-32.
11. Wang le F, Patel M, Razavi HM, Weicker S, Joseph MG, McCormack DG, Mehta S. Role of inducible nitric oxide synthase in pulmonary microvascular protein leak in murine sepsis. Am J Resp Critical Care Med. 2002;165:1634-39.
12. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgman C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337-43.
13. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol. 2000;35:664-9.
14. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharmacy & Pharmacol. 2000;52:213-17.
15. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther. 2003;17:115-21.
16. Paraskevaidis IA, Parissis JT, Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompansated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:243-7.
17. Parissis JT, Farmakis D, Kremastinos DT. Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia. Am J Cardiol. 2005;95:923-4.
18. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453-62.
19. Puttonen J, Kantele S, Kivikko M, Hakkinen S, Harjola VP, Koskinen P, Pentikainen PJ. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46:235-46.
20. Raftopoulos SC. Levosimendan following coronary artery bypass grafting in a patient with end-stage renal failure: a case report. Crit Care Resusc. 2004;6:109-12.
21. Westman L, Järnberg PO. Effects of dobutamine on renal function in normal man. Acta Anaesthesiol Scand. 1986;30:72-5.
22. Kurien S, Warfield KT, Wood CM, Miller WL. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol. 2006;98:1627-30.